Company / Cost of Revenue
Moderna Cost of Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$868.0M
FY2025
5-year range
$0 / $4.7B
FY2021-FY2025
Trend
-40.7%
vs FY2024
Sector context
#19 of 85
Health Care
What the data says
Moderna's cost of revenue of $868M is higher than 78% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 8 years, ranging from $0 in FY2021 to $4.7B in FY2023.
Based on SEC 10-K filings.
$868M in FY2025 with a 5-year CAGR of +155.3%. Top quartile in the Health Care sector.
Improved from $4.7B to $868M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +377.0%
- 5-Year CAGR
- +155.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 85This company $868.0M Sector average $2.0B
▼
-56.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +155.3%, indicating consistent growth.
- In FY2025, cost of revenue decreased 40.7% year-over-year.
- Ranks #19 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $868.0M | -40.7% |
| FY2024 | $1.5B | -68.8% |
| FY2023 | $4.7B | +58562.5% |
| FY2022 | $8.0M | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $8.0M | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026